Atara Financial Statements From 2010 to 2024

ATRA Stock  USD 0.71  0.01  0.74%   
Atara Biotherapeutics financial statements provide useful quarterly and yearly information to potential Atara Biotherapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Atara Biotherapeutics financial statements helps investors assess Atara Biotherapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Atara Biotherapeutics' valuation are summarized below:
Gross Profit
63.6 M
Market Capitalization
85.8 M
Enterprise Value Revenue
10.7692
Revenue
8.6 M
Earnings Share
(2.61)
We have found one hundred twenty available fundamental signals for Atara Biotherapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Atara Biotherapeutics prevailing market performance against the performance between 2010 and 2024 to make sure the company can sustain itself down the road.

Atara Biotherapeutics Total Revenue

10.56 Million

Check Atara Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Atara main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.1 M, Interest Expense of 4 M or Selling General Administrative of 51.3 M, as well as many exotic indicators such as Price To Sales Ratio of 6.02, Dividend Yield of 0.0032 or Days Sales Outstanding of 1.5 K. Atara financial statements analysis is a perfect complement when working with Atara Biotherapeutics Valuation or Volatility modules.
  
This module can also supplement Atara Biotherapeutics' financial leverage analysis and stock options assessment as well as various Atara Biotherapeutics Technical models . Check out the analysis of Atara Biotherapeutics Correlation against competitors.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

Atara Biotherapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets302.7 M165.5 M240.9 M
Slightly volatile
Other Current Liabilities51 M48.5 M20.8 M
Slightly volatile
Total Current Liabilities149.3 M142.2 M46.1 M
Slightly volatile
Other Liabilities131.8 M125.5 M32.1 M
Slightly volatile
Property Plant And Equipment Net42.2 M58.8 M33.5 M
Slightly volatile
Accounts Payable6.1 M3.7 M4.9 M
Slightly volatile
Cash24.7 M26 M54.8 M
Slightly volatile
Non Current Assets Total44.3 M63.6 M35.2 M
Slightly volatile
Non Currrent Assets Other5.1 M4.8 M1.6 M
Slightly volatile
Other Assets0.951.0M
Slightly volatile
Cash And Short Term Investments49.3 M51.9 M179.7 M
Slightly volatile
Common Stock Total Equity12.1 K11.5 K5.1 K
Slightly volatile
Common Stock Shares Outstanding111.2 M105.9 M45.4 M
Slightly volatile
Liabilities And Stockholders Equity302.7 M165.5 M240.9 M
Slightly volatile
Non Current Liabilities Total128.6 M122.5 M44.7 M
Slightly volatile
Other Current Assets8.6 M6.2 M6.8 M
Slightly volatile
Other Stockholder Equity958.7 M1.9 B761.2 M
Slightly volatile
Total Liabilities278 M264.7 M90.8 M
Slightly volatile
Property Plant And Equipment Gross43.7 M74.7 M34.7 M
Slightly volatile
Total Current Assets96.8 M101.9 M194.9 M
Slightly volatile
Common Stock5.7 K11 K4.6 K
Slightly volatile
Property Plant Equipment6.9 M7.2 M21.4 M
Slightly volatile
Net Tangible Assets287 M145.6 M212.9 M
Slightly volatile
Short Term Investments24.6 M25.9 M146.8 M
Pretty Stable
Capital Surpluse1.1 B2.1 B820.9 M
Slightly volatile
Non Current Liabilities Other36.2 M39.3 M22.2 M
Slightly volatile
Short and Long Term Debt400 K450 K490 K
Slightly volatile
Short Term Debt12.8 M12.2 M3.4 M
Slightly volatile
Capital StockK11 K6.5 K
Slightly volatile
Short and Long Term Debt Total40.1 M57.9 M23.3 M
Slightly volatile
Current Deferred Revenue39.9 M77.8 M27.6 M
Slightly volatile
Long Term Debt Total195.2 K219.6 K239.1 K
Slightly volatile
Capital Lease Obligations40.9 M57.9 M24.5 M
Slightly volatile
Net Receivables21.1 M34.1 M7.3 M
Slightly volatile

Atara Biotherapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative51.3 M50.9 M38.4 M
Slightly volatile
Other Operating Expenses212.3 M277.8 M157.4 M
Slightly volatile
Research Development160.2 M219.2 M118.4 M
Slightly volatile
Total Operating Expenses211.4 M269 M156.7 M
Slightly volatile
Non Operating Income Net Other63.1 M60.1 M13 M
Slightly volatile
Interest Income3.2 M4.8 M2.4 M
Slightly volatile
Net Interest Income896.8 K944 K2.3 M
Pretty Stable
Reconciled Depreciation6.3 M4.9 M3.5 M
Slightly volatile
Selling And Marketing Expenses888.8 K999.9 K1.1 M
Slightly volatile

Atara Biotherapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation35.2 M45.4 M26.1 M
Slightly volatile
Begin Period Cash Flow77 M93.1 M57.3 M
Slightly volatile
DepreciationM4.8 MM
Slightly volatile
Capital Expenditures1.2 M1.2 M5.8 M
Pretty Stable
Total Cash From Financing Activities1.9 MM113.2 M
Very volatile
End Period Cash Flow24.7 M26 M64.7 M
Pretty Stable
Change To Netincome3.9 M4.1 M17.9 M
Slightly volatile
Issuance Of Capital Stock30.9 M32.6 M259.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio6.026.335259.237
Slightly volatile
Dividend Yield0.00320.00210.0059
Slightly volatile
Days Sales Outstanding1.5 K1.5 K228
Slightly volatile
Stock Based Compensation To Revenue5.565.29412.8986
Slightly volatile
EV To Sales9.5510.054456.5292
Slightly volatile
Inventory Turnover0.870.91558.0797
Slightly volatile
Days Of Inventory On Hand41939957.136
Slightly volatile
Payables Turnover1.222.41211.1981
Slightly volatile
Sales General And Administrative To Revenue6.245.93823.9863
Pretty Stable
Average Inventory749.4 K713.7 K150.4 K
Slightly volatile
Research And Ddevelopement To Revenue26.8425.564714.8709
Slightly volatile
Cash Per Share0.470.48986.9406
Slightly volatile
Capex To Operating Cash Flow0.0060.00630.0413
Pretty Stable
Days Payables Outstanding144151325
Slightly volatile
Income Quality0.590.69890.717
Pretty Stable
Current Ratio0.680.716211.9892
Slightly volatile
Receivables Turnover0.240.251316.6412
Slightly volatile
Graham Number7.047.413517.9343
Very volatile
Revenue Per Share0.07690.08090.2258
Very volatile
Interest Debt Per Share0.340.59630.3485
Slightly volatile
Debt To Assets0.370.34970.097
Slightly volatile
Operating Cycle1.9 K1.9 K285
Slightly volatile
Days Of Payables Outstanding144151325
Slightly volatile
Ebt Per Ebit1.071.02540.9855
Very volatile
Quick Ratio0.570.604511.7571
Slightly volatile
Net Income Per E B T1.11.00011.0119
Pretty Stable
Cash Ratio0.170.18274.6907
Slightly volatile
Days Of Inventory Outstanding41939957.136
Slightly volatile
Days Of Sales Outstanding1.5 K1.5 K228
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.00631.0522
Slightly volatile
Fixed Asset Turnover0.140.14580.2796
Pretty Stable
Capital Expenditure Coverage Ratio283158605
Slightly volatile
Debt Ratio0.370.34970.097
Slightly volatile
Price Sales Ratio6.026.335259.237
Slightly volatile
Asset Turnover0.07040.05180.0542
Slightly volatile

Atara Biotherapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap70.1 M62.5 M60.9 M
Slightly volatile
Enterprise Value43.1 M77.6 M65.5 M
Slightly volatile

Atara Fundamental Market Drivers

Cash And Short Term Investments51.9 M

Atara Upcoming Events

14th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Atara Biotherapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Atara Biotherapeutics income statement, its balance sheet, and the statement of cash flows. Atara Biotherapeutics investors use historical funamental indicators, such as Atara Biotherapeutics's revenue or net income, to determine how well the company is positioned to perform in the future. Although Atara Biotherapeutics investors may use each financial statement separately, they are all related. The changes in Atara Biotherapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atara Biotherapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Atara Biotherapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Atara Biotherapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue77.8 M39.9 M
Total Revenue8.6 M10.6 M
Cost Of Revenue8.9 M5.8 M
Stock Based Compensation To Revenue 5.29  5.56 
Sales General And Administrative To Revenue 5.94  6.24 
Research And Ddevelopement To Revenue 25.56  26.84 
Capex To Revenue(0.14)(0.15)
Revenue Per Share 0.08  0.08 
Ebit Per Revenue(31.41)(32.98)

Pair Trading with Atara Biotherapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atara Biotherapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atara Biotherapeutics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Atara Biotherapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atara Biotherapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atara Biotherapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atara Biotherapeutics to buy it.
The correlation of Atara Biotherapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atara Biotherapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atara Biotherapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atara Biotherapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Atara Biotherapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Atara Biotherapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atara Biotherapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atara Biotherapeutics Stock:
Check out the analysis of Atara Biotherapeutics Correlation against competitors.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Complementary Tools for Atara Stock analysis

When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Is Atara Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atara Biotherapeutics. If investors know Atara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atara Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.61)
Revenue Per Share
0.081
Quarterly Revenue Growth
13.457
Return On Assets
(0.62)
Return On Equity
(20.15)
The market value of Atara Biotherapeutics is measured differently than its book value, which is the value of Atara that is recorded on the company's balance sheet. Investors also form their own opinion of Atara Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Atara Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atara Biotherapeutics' market value can be influenced by many factors that don't directly affect Atara Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atara Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Atara Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atara Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.